Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2018

View Archived Issues

Phase II results of JAK1/2 inhibitor baricitinib for the treatment of systemic lupus erythematosus

Use of autologous adipose-derived regenerative cells for the treatment of severe thermal burns

Novel small molecule targeting STAT5/6 reverses allergic airway disease in mice

Kinase inhibitors for familial Parkinson's may work in sporadic disease

Positive topline results presented for phase IIb study of RTB-101

PTBP1 identified as a SASP regulator that does not affect the senescence growth arrest

CFDA approves INDs for Innovent's IBI-101 and IBI-307

Researchers develop CD41-KO murine model of immune thrombocytopenia

DSMB recommends early termination of phase III study of Neutrolin owing to efficacy

New phase III trial explores subcutaneous fixed-dose combination of pertuzumab and trastuzumab

Otonomy initiates additional phase III trial of Otividex for Meniere's disease

Phase III studies of KX2-391 in actinic keratosis achieve primary endpoint

DTX-401 begins phase I/II study for glycogen storage disease type Ia

Phase I study of BTK inhibitor PRN-2246 confirms CNS exposure and promising tolerability

Medivir reports promising topline joint structure outcomes from phase IIa extension study of MIV-711

Chronic treatment with BBB-penetrable EPO analogue shows protective effects in AD mice model

Proclara advances NPT-189 for systemic amyloidosis and NPT-088 for Alzheimer's

First data presented from phase I/II study of dolutegravir dispersible tablet pediatric formulation

Continued virologic suppression in subjects with resistance mutation switching to E/C/F/TAF

Data presented for the 48-week viral suppression across age categories in the LIVING study

Viamet Pharmaceuticals describes cytochrome P450 11B2 inhibitors

Meiji Seika Pharma identifies phosphodiesterase PDE4 inhibitors

Minoryx Therapeutics patents beta-1 galactosidase mutant chaperones